Interfering with this regulatory loop not only reducessymmetric divisions (and promotes asymmetric divisions) of CRC TICs, but alsorestores the susceptibility of cancer cells to cetuximab, an inhibitor of EGFR thatis used to treat CRC (Hwang et al.,2014). The gene discussed is EGFR; the disease is colorectal carcinoma.